Mobile Edition
Print
Get the Mag
Weekly UpdatesUS healthcare major Johnson & Johnson and Irish neuroscience-based biotech firm Elan have signed an agreement whereby J&J will acquire all the assets and rights related to Elan's Alzheimer's disease immunotherapy programme through a new company, and will also invest $1bn in Elan in exchange for an 18.4% holding. J&J will commit up to $500m to continue, with Elan's partner Wyeth, the development and launch of bapineuzumab, which is currently being evaluated for slowing the progress of Alzheimer's disease. Elan will receive a 49.9% homing in the new JW company, with a similar share of any profits and future royalty payments.
|
More Resources
|
|||
US healthcare major Johnson & Johnson and Irish neuroscience-based biotech firm Elan have signed an agreement whereby J&J will a
COPYRIGHT 2009 Society of Chemical
Industry Reproduced with permission of the copyright holder. Further reproduction or distribution is prohibited without permission.
Copyright 2009 Gale, Cengage Learning. All rights reserved. Gale Group is a Thomson Corporation Company. NOTE: All illustrations and photos have been removed from this article. |
|||
FEED